Apogenix to Present at Five Upcoming International Conferences
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that company representatives will attend several upcoming international conferences. In a total of five presentations, Apogenix will give updates on its hexavalent TNF superfamily receptor agonists (HERA-ligands) as well as its phase III-ready lead drug candidate asunercept.